Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug551 | CAP-1002 Allogeneic Cardiosphere-Derived Cells Wiki | 1.00 |
drug1158 | Electrical Stimulation Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D009133 | Muscular Atrophy NIH | 0.71 |
D001284 | Atrophy NIH | 0.71 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Unfortunately, hospital-acquired weakness is highly prevalent among COVID-19 hospitalized patients, who often require prolonged bed-rest or paralytics for an extended period of time in order to maintain oxygenation. Prolonged bed rest has been associated with pronounced loss of muscle mass that can exceed 10% over the 1st week, which leads to functional impairment and complications post-hospital discharge. Physical therapy and in-hospital mobility program may reduce the incident of hospital-acquired weakness, but they are often impractical for COVID-19 patients. In particular, conventional mobility programs are challenging for those who are being treated in an intensive Care Unit. The purpose of this study is to test feasibility and proof-of-concept effectiveness of daily use of lower extremity electrical stimulation (EE) therapy, as a practical solution to retain lower extremity muscle mass, to address chronic morbid consequences of COVID-19 including hospital-acquired weakness.
Description: Muscle fiber activation will be assessed using wireless surface electromyogram
Measure: Change in muscle function Time: baseline to 4 weeksDescription: Muscle fatigue will be assessed using wireless surface electromyogram sensors by measuring changes in the power spectrum of the measured muscle activation at the first 10 minutes of EE application compared to last 10min of EE application during 60min EE application.
Measure: muscle fatigue Time: baseline to 4 weeksDescription: Tissue oxygen saturation will be assessed using near infrared spectroscopy
Measure: Change in tissue oxygen saturation Time: baseline to 4 weeksDescription: Ankle circumference as a surrogate of muscle atrophy and/or edema will be measured using a standard tape
Measure: Ankle circumference Time: baseline to 4 weeksDescription: Thigh circumference as a surrogate of muscle atrophy and/or edema will be measured using a standard tape
Measure: Thigh circumference Time: baseline to 4 weeksDescription: Thigh circumference as a surrogate of muscle atrophy and/or edema will be measured using a standard tape
Measure: Foot circumference Time: baseline to 4 weeksDescription: Venous return flow will be assessed using Doppler Ultrasonography
Measure: Venous Return Flow Time: baseline to 4 weeksDescription: Frailty will be assessed using frailtymeter
Measure: Frailty Time: baseline to 4 weeksDescription: Length of stay will be assessed through the patient medical record
Measure: Length of stay Time: Through study completion, an average of 1 yearDescription: Major adverse events will be assessed through the patient medical record
Measure: Major adverse events Time: Through study completion, an average of 1 yearDescription: The Lawton Instrumental Activities of Daily Living Scale (IADL) survey will be used to assess IADL at one month post discharge. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men to avoid potential gender bias.
Measure: instrumental activities of daily living scale Time: one month post dischargeDescription: Community engagement will be assessed by Aging Life-Space Assessment (LSA) survey at one month post discharge. The scale ranges from 0 to 9, higher value indicates higher community engagement.
Measure: Community engagement Scale Time: one month post dischargeDescription: Depression will be assessed by the Center for Epidemiological Studies Depression (CES-D) questionnaire. Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The CES-D also provides cutoff scores (e.g., 16 or greater) that aid in identifying individuals at risk for clinical depression.
Measure: Depression scale Time: one month post dischargeDescription: weight loss as a surrogate of muscle atrophy will be assessed at 4 weeks compared to baseline
Measure: Weight loss Time: 4 weeksDescription: Lower extremity numbness will be assessed using vibration pressure threshold test
Measure: Neuropathy Time: baseline to 4 weeksDescription: Muscle strength will be assessed using a foot dynamo-meter
Measure: Change in muscle strength Time: baseline to 4 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports